AstraZeneca signs a deal worth up to $247M with US-based Absci to harness its AI tech for large-scale protein analysis and design an antibody to fight cancer (Michael Peel/Financial Times) 03-12-2023
Michael Peel / Financial Times: AstraZeneca signs a deal worth up to $247M with US-based Absci to harness its AI tech for large-scale protein analysis and design an antibody to fight cancer — Deal with Absci is the latest between big pharma and tech companies to build new disease treatments Lees verder op Tech Meme